Pharmacies to offer rivaroxaban starter packs

Candace Stuart | | Cardiovascular Business | Vascular & Endovascular

Janssen Pharmaceuticals plans to make a starter pack of the anticoagulant rivaroxaban available in pharmacies in October. The starter pack is designed to simplify dosing for patients at risk of deep vein thrombosis or pulmonary embolism during the first 30 days of treatment.

The FDA approved rivaroxaban (Xarelto), a Factor Xa inhibitor, in late 2012 for the treatment of deep vein thrombosis or pulmonary embolism and to reduce the risk of recurrences. The starter pack provides a 15mg dose taken twice daily for the first 21 days, followed by once-daily doses of 20mg through the remaining portion of the 30-day treatment.

Candace Stuart, Contributor

Related Content

IVUS-guided PCI reduces risks in patients with diabetes
LAAC with Watchman FLX reduces bleeding risks after AFib ablation
Bioresorbable BTK stent superior to ballon angioplasty at 2 years
Shockwave Medical’s IVL technology delivers more positive outcomes for PAD patients
Standing desks fail to lower blood pressure or minimize heart risks—they may even do damage
IVL vs. RA for chronic total occlusion PCI: Key data cardiologists should know

Around the web

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Radiology Business
What does radiology have to do with climate change?

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."